January 10, 2018
Polsinelli Strengthens IP Litigation Practice, Adding Former Pharma Legal Executive Andrew Solomon

Polsinelli, an Am Law 100 firm, announced today that Andrew M. (Andy) Solomon has joined its St. Louis office, adding to the firm’s Intellectual Property Litigation practice.

Solomon focuses his legal work on the intellectual property, regulatory, and commercial strategies that enable the timely launch of pharmaceutical products. He previously served as Vice President and Assistant General Counsel at Perrigo Company plc, a leading global healthcare company, serving as general counsel for its Prescription Pharmaceuticals business and global head of its intellectual property practice. When Solomon joined Perrigo in 2003, the company was just launching its generic prescription business. During his tenure and thanks, in part, to numerous successful litigation results, the business now posts more than $1 billion in annual sales in calendar year 2016. In January 2010, an industry report by RBC Capital Markets cited Perrigo has having “the best overall litigation success rate, taking top honors in best overall success rate, best batting average in court and highest percentage of cases settled/dropped” for the years from 2000 - 2009.

Drawing upon this and other experience over his 30 year career in the industry, Solomon counsels clients in handling a variety of intellectual property and commercial matters, including portfolio development, conducting transactional due diligence and negotiating and executing a wide range of agreements. He is also a registered patent attorney.

“We’re excited and proud to have Andy join us, further strengthening our national Hatch-Waxman Litigation practice, which is recognized as an industry leader,” said Gary E. Hood, who chairs Polsinelli’s Intellectual Property Division and heads the firm’s Hatch-Waxman group. “Our clients benefit from the skills and insights he’s sharpened over many years spent in-house at leading pharmaceutical companies and he’s a great resource to our attorneys as we continually strive to be client-focused in all we do.”

Polsinelli has one the largest Intellectual Property practices in the nation, comprised of more than 120 attorneys, patent agents and scientists. The practice recently earned a Tier 1 ranking, the highest score, in U.S. News & World Report’s 2018 “Best Law Firms” report.

The firm’s Hatch-Waxman team has deep experience leading Abbreviated New Drug Application (ANDA) cases and represents some the world’s largest, best-known, and most influential generic, brand, and specialty pharmaceutical companies, litigating everything from blockbuster products to smaller market and specialty pharmaceuticals, in both first-to-file and later filer cases.

“I’m thrilled to join a firm that has a Hatch-Waxman group filled with a talented team of attorneys and strong national presence,” Solomon said. “This is an important moment for the pharmaceutical industry, as the Food and Drug Administration’s pathway for the approval of drugs and biologics continues to evolve. It’s great to have the opportunity to leverage my own experience in helping clients navigate this complex environment.”

Solomon is a graduate of the University of Missouri-Columbia School of Law and holds a Bachelor of Science degree in Chemical Engineering.

For more information, please contact Carrie Trent at